Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 8 of 101, showing 5 Applications out of 505 total, starting on record 36, ending on 40

# Protocol No Study Title Investigator(s) & Site(s)

36.

ECCT/23/01/06   FENHANCE
    A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULTread more
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
Aga Khan University, Nairobi
 
View

37.

ECCT/24/02/10   IMBrave
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCEDread more
Principal Investigator(s)
1. Dr. Pauline Njoki Njiraini
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

38.

ECCT/23/06/04   ARNASA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE       
Principal Investigator(s)
1. Dr Jacqueline Mirera
Site(s) in Kenya
1. Clinical Research Health Network (CREA-N) (Machakos county)
2. KEMRI-CRDR Siayaread more
View

39.

ECCT/22/12/03   heredERA
    A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO +read more
Principal Investigator(s)
1. Mansoor Saleh
2. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. Internationalread more
View

40.

ECCT/23/01/01   PROHER
    A PHASE IIIB, MULTINATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PATIENT PREFERENCE FOR HOME ADMINISTRATION OF FIXED-DOSE COMBINATION OF PERTUZUMAB ANDread more
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Mansoor Saleh
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. Internationalread more
View